Published in Expert Opin Drug Saf on August 23, 2012
Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations. Expert Opin Drug Saf (2012) 0.80
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics (2014) 0.80
Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). Int Urol Nephrol (2015) 0.75
Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study. Cardiorenal Med (2015) 0.75
Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 10.65
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med (2004) 6.52
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant (2004) 4.27
Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int (2003) 3.90
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
The burden of kidney disease: improving global outcomes. Kidney Int (2004) 2.94
Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol (2004) 2.47
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Latest US KDOQI Anaemia Guidelines update--what are the implications for Europe? Nephrol Dial Transplant (2007) 2.12
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis (2008) 2.02
Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med (2013) 2.00
Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2004) 1.93
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol (2011) 1.84
Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2004) 1.83
Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2004) 1.81
Mini-peritoneal equilibration test: A simple and fast method to assess free water and small solute transport across the peritoneal membrane. Kidney Int (2005) 1.80
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol (2008) 1.76
Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis (2003) 1.73
Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol (2010) 1.70
Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol Dial Transplant (2004) 1.59
Effects of ionized sodium concentrations on ultrafiltration rate in peritoneal dialysis using lactate and lactate/bicarbonate solutions. Perit Dial Int (2009) 1.57
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis (2005) 1.54
Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol (2006) 1.47
Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis (2011) 1.45
Current Evidence in Haemodiafiltration. Blood Purif (2015) 1.41
IgA nephritis: ACE inhibitors, steroids, both or neither? Nephrol Dial Transplant (2006) 1.41
Stopping a medical research project for financial reasons. Nephrol Dial Transplant (2003) 1.40
Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol (2007) 1.40
Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach? Nephrol Dial Transplant (2011) 1.39
Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int (2013) 1.35
C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol (2008) 1.34
The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant (2004) 1.18
Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol (2009) 1.13
The epidemiology of end-stage renal disease in Iran in an international perspective. Nephrol Dial Transplant (2002) 1.12
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant (2010) 1.11
Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis (2006) 1.11
The quality of dialysis water. Nephrol Dial Transplant (2003) 1.10
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant (2008) 1.10
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant (2010) 1.10
Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol (2002) 1.09
What we know about oxidative stress in patients with chronic kidney disease on dialysis--clinical effects, potential treatment, and prevention. Semin Dial (2011) 1.07
Biosimilars and regulatory authorities. Nephron Clin Pract (2010) 1.06
Increasing home based dialysis therapies to tackle dialysis burden around the world: a position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Nephrology (Carlton) (2011) 1.06
Hemodialysis vascular access training and practices are key to improved access outcomes. Am J Kidney Dis (2010) 1.03
Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr (2005) 1.01
Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2013) 1.01
The regulatory framework of biosimilars in the European Union. Drug Discov Today (2011) 0.98
Sodium balance in hemodialysis therapy. Semin Dial (2003) 0.97
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol (2008) 0.95
The role of blood volume reduction in the genesis of intradialytic hypotension. Am J Kidney Dis (2002) 0.95
IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. J Nephrol (2013) 0.94
Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med (2012) 0.94
C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant (2011) 0.93
International Study of Health Care Organization and Financing for renal replacement therapy in Italy: an evolving reality. Int J Health Care Finance Econ (2007) 0.93
COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant (2012) 0.92
Overfill of peritoneal dialysis bags as a cause of underestimation of ultrafiltration failure. Perit Dial Int (2006) 0.92
Sodium removal and sodium concentration during peritoneal dialysis: effects of three methods of sodium measurement. Nephrol Dial Transplant (2004) 0.91
Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol (2011) 0.90
Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant (2013) 0.90
High-flux versus low-flux membranes for end-stage kidney disease. Cochrane Database Syst Rev (2012) 0.90
Convection versus diffusion in dialysis: an Italian prospective multicentre study. Nephrol Dial Transplant (2003) 0.89
Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl. Clin Nephrol (2012) 0.89
Influence of body mass index on the association of weight changes with mortality in hemodialysis patients. Clin J Am Soc Nephrol (2013) 0.89
Dialysis adequacy today: a European perspective. Nephrol Dial Transplant (2012) 0.89
Cinacalcet for cardiovascular disease in patients undergoing dialysis. N Engl J Med (2013) 0.89
Hypertension in dialysis: pathophysiology and treatment. J Nephrol (2002) 0.88
Clinical evidence on hemodiafiltration: a systematic review and a meta-analysis. Semin Dial (2014) 0.88
Dialysate composition. Contrib Nephrol (2008) 0.87
European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 0.86
Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies. Expert Rev Hematol (2014) 0.86
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl (2004) 0.85
Are natriuretic peptides a reliable marker for mortality in ESRD patients? Nephrol Dial Transplant (2009) 0.85
Long-term outcome in hemodialysis: morbidity and mortality. J Nephrol (2004) 0.84
Automatic adaptive system dialysis for hemodialysis-associated hypotension and intolerance: a noncontrolled multicenter trial. Am J Kidney Dis (2011) 0.84
Anemia management in patients on peritoneal dialysis. Contrib Nephrol (2012) 0.83
Can immunosuppressive therapy be useful in IgA nephropathy when the 'Point of No Return' has already been exceeded? Nephron (2002) 0.83
Chronic kidney disease-associated anemia: new remedies. Curr Opin Investig Drugs (2010) 0.83
Kidney and liver involvement in cryoglobulinemia. Semin Nephrol (2002) 0.83
ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study. J Nephrol (2006) 0.83
Transport of peritoneal membrane assessed before and after the start of peritoneal dialysis. Nephrol Dial Transplant (2009) 0.83
Effectiveness of sodium and conductivity kinetic models in predicting end-dialysis plasma water sodium concentration: preliminary results of a single-center experience. Hemodial Int (2007) 0.82
Geriatric nephrology. J Nephrol (2010) 0.82
Renal anemia: comparing current Eastern and Western European management practice (ORAMA). Ren Fail (2008) 0.81
Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star? Expert Opin Pharmacother (2013) 0.81
Sodium removal during pre-dilution haemofiltration. Nephrol Dial Transplant (2003) 0.81
CKD patients: the dilemma of serum PTH levels. Nephron Clin Pract (2010) 0.81
Pure red cell aplasia secondary to treatment with erythropoietin. Artif Organs (2003) 0.80
Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment. Nephrol Dial Transplant (2010) 0.80
Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study. Nephron Clin Pract (2010) 0.80
Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2013) 0.79
A new initiative in nephrology: 'Kidney disease: improving global outcomes'. Contrib Nephrol (2005) 0.79
Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients. Semin Nephrol (2004) 0.79
The QUEST initiative anemia study in transplant patients: rationale and study protocol. J Nephrol (2007) 0.78
Methoxypolyethylene glycol-epoetin beta for the treatment of anemia associated with chronic kidney disease. Drugs Today (Barc) (2008) 0.78
Recombinant human epoetin beta in the treatment of renal anemia. Ther Clin Risk Manag (2007) 0.78
The QUEST initiative anemia study in ESRD: rationale and study protocol. J Nephrol (2007) 0.78
The First European Renal Association-European Dialysis and Transplant Association CKD Anaemia Physician Behaviours Survey: key findings. J Nephrol (2008) 0.77